arrow
E

Erfan Nur

Amsterdam University Medical Centers
H指数:27
被引数:3,177

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study

eltrombopag添加到标准免疫抑制治疗中作为一线疗法治疗重症再生障碍性贫血:EBMT-SAAWP RACE研究3期随机优越性研究的长期结果

2026-07-280
OAAI
Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children

在大多数镰状细胞病患者中检测不到羟基脲水平,尤其是在幼儿中

2026-07-030
OAAI
Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea

β地中海贫血患者接种COVID-19疫苗后的体液和细胞免疫应答

2025-11-280
OAAI
Iron Deficiency in HbSC Disease Treated With Repetitive Phlebotomy Is Associated With Fewer Sickle Cell Disease-Related Complications

HbSC疾病患者经反复放血治疗后,缺铁与较少的镰状细胞病相关并发症相关。

2025-09-040
OAAI
Outcomes following different upfront stem cell transplantation strategies for multiple myeloma: a statistical perspective on behalf of the Chronic Malignancies Working Party of the EBMT

不同初始干细胞移植策略治疗多发性骨髓瘤的结局:EBMT慢性恶性疾病工作组从统计学角度进行的分析

2025-07-300
OAAI
Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT

异基因造血细胞移植治疗费城染色体阳性急性淋巴细胞白血病的老年患者。EBMT急性白血病工作组的研究。

2025-07-160
PRE
Model-Informed Precision Dosing of Busulfan for Children and Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Critical Evaluation of Current PK Models and Dose Recommendations

基于模型的硼替佐米精确剂量调整用于接受异基因造血干细胞移植的儿童和成人:对当前药代动力学模型和剂量建议的批判性评估

2025-06-220
OAAI
Assessment of neurocognitive functioning in sickle cell disease and thalassaemia and the association with silent cerebral infarcts, cerebral haemodynamics and oxygen metabolism

镰状细胞病和β地中海贫血患者神经认知功能的评估及其与静息性脑梗死、脑血流动力学和氧代谢的关联

2025-06-040
PRE
COVID-19 in patients affected by red blood cell disorders, results from the European registry ERN-EuroBloodNet
2025-04-160
OAAI
Time-restricted versus standard-duration immunosuppression after allogeneic hematopoietic stem cell transplantation: Results of the prospective randomized HOVON-96 trial
2024-12-110
OAAI